Security record · archived quarter
IHE
iShares U.S. Pharmaceuticals ETF · Financial Services · Asset Management
5Tracked holders
—Δ holders
3.48MShares held
$230.98MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 52 | +4 | 6.31M | $625.68M | +6 | −2 |
| Q1 2026 | 49 | +1 | 5.21M | $450.70M | +3 | −2 |
| Q4 2025 | 48 | +1 | 4.98M | $422.06M | +1 | — |
| Q3 2025 | 7 | +1 | 3.46M | $251.38M | +1 | — |
| Q2 2025 | 3 | 0 | 3.03M | $198.38M | — | — |
| Q1 2025 | 2 | -2 | 3.17M | $223.35M | — | −2 |
| Q4 2024 | 4 | +1 | 3.32M | $218.11M | +2 | −1 |
| Q3 2024 | 3 | -2 | 3.37M | $237.66M | — | −2 |
| Q2 2024 | 5 | — | 3.48M | $230.98M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fisher Asset Management ✦ | 3.44M | — | $228.21M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 23.91K | — | $1.59M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Marshall Wace ✦ | 6.36K | — | $422,061 | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Two Sigma Investments ✦ | 6.30K | — | $417,816 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 5.21K | — | $345,594 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 193 holders, 7.24M shares, $621.44M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API